Bedaquiline is the world's first diarylquinoline anti-mycobacterial drug, specifically indicated for the treatment of adult and pediatric (aged 2 years and older with a body weight ≥ 8 kg) patients with pulmonary tuberculosis who are resistant to at least rifampicin and isoniazid.
What Are the Purchase Channels for Bedaquiline?
Overseas Purchase
Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries or regions where bedaquiline has been marketed.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase via Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions can usually provide legal import channels as well as professional consultation and guidance.
Precautions for Bedaquiline Administration
Requirements for Electrocardiogram (ECG) Monitoring
Baseline ECG test before medication initiation.
Regular re-examination at the 2nd week of treatment and during subsequent treatment periods.
Immediate discontinuation of the drug is required if QTc interval exceeds 500 ms or significant ventricular arrhythmia occurs.
Specifications for Combination Therapy
Must be used in combination with at least 3 other sensitive drugs.
Avoid concurrent use with strong or moderate CYP3A4 inducers.
When used concomitantly with CYP3A4 inhibitors, close monitoring of liver function is necessary.
Administration in Special Populations
Patients with hepatic impairment: No dosage adjustment is required for mild to moderate impairment; use with caution and monitor for adverse reactions in severe impairment.
Patients with renal impairment: No dosage adjustment is required for mild to moderate impairment; use with caution in patients with severe impairment or end-stage renal disease.
Pediatric patients: Restricted to patients aged 2 years and older with a body weight ≥ 8 kg.
Pregnant women: The benefits and risks must be carefully weighed, as sufficient data to evaluate the risks are lacking.
Lactating women: Breastfeeding is not recommended unless infant formula is unavailable. If an infant is exposed to bedaquiline through breast milk, monitor for relevant adverse reactions such as hepatotoxicity.
Identification of Authentic Bedaquiline
Package Feature Recognition
20 mg tablets: White to almost white, rectangular, functionally scored tablets with notches on both sides; one side is imprinted with "2" and "0", and the other side is blank.
100 mg tablets: White to almost white, round, biconvex tablets; one side is imprinted with "T" above "207", and the other side is imprinted with "100".
Dosage Form and Specification Verification
Confirm that the drug specifications are consistent with the prescription.
Check that the tablet markings match the official descriptions.
Verify the completeness of the manufacturer's information.
Quality Abnormality Screening
Storage conditions: The drug should be stored in its original packaging at 25°C, protected from light and moisture.
Visual inspection: Observe whether the tablets are intact and whether the color complies with the description.
